Earnings Call · Q2 FY2024·2024-08-09

Q2 24EPS +28.92%·Rev n/aQ1 24EPS +16.28%·Rev n/aQ4 23EPS -1.20%·Rev n/aQ3 23EPS +19.78%·Rev n/a⚠ consensus missing

RELMADA THERAPEUTICS, INC. RLMD

Tim McCarthy

Sergio Traversa — Chief Executive Officer

Maged Shenouda — Chief Financial Officer

0.0%1d on move date−0.1% vs SPY3d+11.7%5d+8.7%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RLMD calls or request research access.

More RLMD calls Browse calls Request research access